Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with an operating company. Its stated focus is on businesses involved in the development, manufacturing, distribution or commercialization of pharmaceutical products and related healthcare technologies.

The company does not operate as a pharmaceutical manufacturer or healthcare services provider and does not have its own portfolio of drugs, medical products or commercial operations. Instead, it holds funds raised through its public offering while seeking a suitable merger, acquisition or similar transaction, primarily with a company connected to the U.S. pharmaceutical and healthcare markets.

Information about a completed acquisition, operating subsidiaries, commercial products and executive leadership is limited in publicly available company materials. Until it completes a business combination, Drugs Made In America Acquisition Corp.'s activities are principally limited to evaluating potential targets and meeting the administrative and regulatory obligations of a publicly traded SPAC.

Key Stats

• Today's Range: $10.88 to $10.89
• 50-Day Range: $10.72 to $10.94
• 52-Week Range: $10.30 to $10.89
• Volume: 1,034 shs
• Average Volume: 77,062 shs
• Market Capitalization: $264.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Drugs Made In America Acquisition Stock Analysis - MarketRank™

Drugs Made In America Acquisition scored higher than 2% of companies evaluated by MarketBeat, and ranked 585th out of 590 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Drugs Made In America Acquisition has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Drugs Made In America Acquisition has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.37% of the float of Drugs Made In America Acquisition has been sold short.

Short Interest Ratio / Days to Cover

Drugs Made In America Acquisition has a short interest ratio ("days to cover") of 101, which indicates bearish sentiment.

Change versus previous month

Short interest in Drugs Made In America Acquisition has recently decreased by 2.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Drugs Made In America Acquisition does not currently pay a dividend.

Dividend Growth

Drugs Made In America Acquisition does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Drugs Made In America Acquisition this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Drugs Made In America Acquisition insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.90% of the stock of Drugs Made In America Acquisition is held by insiders.

Percentage Held by Institutions

Drugs Made In America Acquisition has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:DMAA
• CIK: 2028614
• Web: dmaacorp.com
• Phone: (646) 726-7074
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,280,000
• Free Float: 24,059,000
• Market Cap: $264.26 million
• Optionable: N/A
• Beta: N/A